Biologists at Indiana University Bloomington have shown that the surfaces of plant leaves are coated with a diverse array of ...

RBD-7022 is under clinical development by Suzhou Ribo Life Sciences and currently in Phase I for Hyperlipidemia.

The investigational therapy works to impede the expression of genes that cause the body to store fat as a potential treatment ...

Opens in a new tab or window In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led ...

RNA interference (RNAi), meanwhile, is a natural defense mechanism against exogenous genes but can counter the positive effects of mRNA. The new proof of concept study published in ACS Nanoscience ...

Silence Therapeutics ( (SLN) ) has shared an announcement.

RNA interference (RNAi), meanwhile, is a natural defense mechanism against exogenous genes but can counter the positive effects of mRNA. The new proof of concept study published in ACS Nanoscience ...

In upcoming research—using techniques like in situ hybridization (ISH) and RNA interference (RNAi) to "hunt down" these genes—Jacob Machado said the team can study "what happens to the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigatio ...

Pharmaceuticals announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) ...